编程释放 METTL3-14 抑制剂 微针通过减少 Drp1 m6A 修改介导的线粒体裂变来保护心肌功能
Boyue Huang1, Liu Xie2,3, Ming Ke2
1Department of Anatomy, and Laboratory of Neuroscience and Tissue Engineering, Basic Medical College, Chongqing Medical University, Chongqing 400016, China.
ACS applied materials & interfaces
|September 27, 2023
概括
这项研究表明,使用微针来抑制METTL3-14可以通过保护心肌细胞和减少纤维化,改善心肌梗塞 (MI) 后的心脏功能. 这种新型药物输送系统为心脏病发作治疗提供了一个有前途的治疗方法.
科学领域:
- 生物化学 生物化学
- 心血管生物学 心血管生物学
- 生物材料科学 生物材料科学
背景情况:
- 心肌梗塞 (MI) 涉及心肌细胞损失和心脏重塑,受到动态RNA修饰的影响,如m6A.
- 线粒体动力学 (融合/裂变) 对心脏平衡至关重要,它们的不平衡有助于后心脏病损伤.
- 目前的MI疗法在时间和细胞向方面存在局限性.
研究的目的:
- 调查针对MI中METTL3-14的治疗潜力.
- 评估用于心脏病发作治疗的双层编程药物释放微针 (DPDMN) 系统.
- 阐明METTL3抑制影响心肌细胞死亡和纤维化的分子机制.
主要方法:
- 利用缺氧缺血和TGF-β1诱导的细胞模型来评估METTL3-14抑制效应.
- 装有METTL3抑制剂的DPDMN用于治疗MI的老鼠模型.
- 进行RIP测定和机械学调查以确认分子标和途径.
主要成果:
- 抑制METTL3-14通过减轻线粒体碎片化和肌纤维细胞转化在体外减少心肌细胞死亡.
- 在MI小鼠中,DPDMN治疗显著改善了心脏功能,减少了心脏病发作的大小,并减少了纤维化.
- DPDMN证明了双相药物释放,针对早期心肌细胞救援和晚期纤维化抑制.
- 证实METTL3抑制通过影响其mRNA的m6A修饰来降低Drp1蛋白水平,从而减少线粒体碎片化.
结论:
- 用DPDMN针对METTL3-14是一个强大的治疗策略.
- DPDMN系统提供了一种多功能和有效的方法来治疗心脏病发作,通过使精确的,双相药物输送.
- 这项研究为将MI治疗的微针技术转化为临床实践提供了坚实的基础.
相关概念视频
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...